Monday, April 19, 2010: 2:29 PM
Regency Ballroom VI
Background:Mumps, a vaccine-preventable disease, is characterized by fever and inflammation of the salivary glands; complications include orchitis, oophoritis, deafness, and meningoencephalitis. In September 2009, we identified a mumps outbreak in NJ linked to a larger outbreak of >400 cases in NY and
Objectives:We investigated the NJ outbreak to identify the source, characterize the outbreak, and develop control measures.
Methods:We defined a probable case as a clinically-compatible illness; a confirmed case had either laboratory-confirmation or an epidemiologic link to another confirmed or probable case. We interviewed patients and their physicians by telephone and collected laboratory information.
Results:As of December 3, a total of 80 confirmed and probable cases were reported among NJ residents; 76% were male (median: 18 years, range: 1–61 years). Complications were reported among 11 (13.8%) patients: orchitis (10) and oophoritis (1). No hospitalizations or deaths have been reported. Mumps vaccination status was known for 69 (86.3%) patients; receipt of two mumps vaccine doses included two (25.5%) of eight patients aged 1–6 years, 29 (90.6%) of 32 patients aged 7–18 years, and 16 (57.1%) of 28 patients aged 19–52 years. Genotype G virus was isolated from tested patients.
Conclusions:Extensive and ongoing transmission of mumps has been identified in multiple locations in the United States and Canada and has resulted in the largest mumps outbreak in the